We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · January 28, 2019

Effect of Nonmyeloablative HSCT vs Continued Disease-Modifying Therapy on Disease Progression in Relapsing–Remitting MS

JAMA: The Journal of the American Medical Association

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial
JAMA 2019 Jan 15;321(2)165-174, RK Burt, R Balabanov, J Burman, B Sharrack, JA Snowden, MC Oliveira, J Fagius, J Rose, F Nelson, AA Barreira, K Carlson, X Han, D Moraes, A Morgan, K Quigley, K Yaung, R Buckley, C Alldredge, A Clendenan, MA Calvario, J Henry, B Jovanovic, IB Helenowski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading